Targeted drug and gene delivery is the key for precision therapy. Lipid nanoparticles as non-
viral vectors have attracted extensive attentions in treating a variety of diseases, such as …

Abstract Solid Lipid Nanoparticles (SLN), the first type of lipid-based solid carrier systems in
the nanometer range, were introduced as a replacement for liposomes. SLN are aqueous …

Lipid-based drug-delivery systems have evolved from micro-to nano-scale, enhancing the
efficacy and therapeutic applications of these delivery systems. Production of lipid-based …

Lipid nanoparticle (LNP)-based drug delivery systems have become the most clinically
advanced non-viral delivery technology. LNPs can encapsulate and deliver a wide variety of …

In the golden age of pharmaceutical nanocarriers, we are witnessing a maturation stage of
the original concepts and ideas. There is no doubt that nanoformulations are extremely …

The last few years have witnessed a great advance in the development of nonviral systems
for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most …

Solid lipid nanoparticles are at the forefront of the rapidly developing field of nanotechnology
with several potential applications in drug delivery, clinical medicine, and research, as well …

Lipid nanoparticles (LNPs) have gained prominence as primary carriers for delivering a
diverse array of therapeutic agents. Biological products have achieved a solid presence in …

Over the past decade, the therapeutic potential of nanomaterials as novel drug delivery
systems complementing conventional pharmacology has been widely acknowledged …

Most of the biologically active compounds are struggle with low solubility and therefore low
bioavailability, biological degradation and inadvertent intrinsic side effects. To overcome …